Harvard Bioscience (HBIO) Total Debt (2010 - 2026)

Harvard Bioscience (HBIO) has reported Total Debt for 17 consecutive years, with $36.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt rose 5.21% year-over-year to $36.7 million in Q2 2026; TTM through Jun 2026 was $36.7 million, a 5.21% increase from a year earlier, with the FY2025 full-year figure at $35.9 million, down 2.94% from the prior year.
• Total Debt was $36.7 million for Q2 2026 at Harvard Bioscience, up from $36.2 million in the prior quarter.
• Over five years, Total Debt peaked at $52.0 million in Q3 2022 and troughed at $34.0 million in Q3 2025.
• A 5-year average of $41.8 million and a median of $40.4 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt climbed 13.49% in 2022 and fell 18.78% in 2023, its largest moves.
• Over 5 years, Total Debt stood at $50.6 million in 2022, then decreased by 16.22% to $42.4 million in 2023, then fell by 12.88% to $37.0 million in 2024, then declined by 2.94% to $35.9 million in 2025, then gained by 2.26% to $36.7 million in 2026.
• The last three Total Debt figures came in at $36.7 million (Q2 2026), $36.2 million (Q1 2026), and $35.9 million (Q4 2025), per Business Quant data.